CN111690681A - Real-time monitoring method for cervical cancer SiHa cell line beta-hCG - Google Patents

Real-time monitoring method for cervical cancer SiHa cell line beta-hCG Download PDF

Info

Publication number
CN111690681A
CN111690681A CN202010590308.1A CN202010590308A CN111690681A CN 111690681 A CN111690681 A CN 111690681A CN 202010590308 A CN202010590308 A CN 202010590308A CN 111690681 A CN111690681 A CN 111690681A
Authority
CN
China
Prior art keywords
hcg
beta
siha
cells
urine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202010590308.1A
Other languages
Chinese (zh)
Inventor
傅善基
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Qilu Hospital of Shandong University
Original Assignee
Qilu Hospital of Shandong University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Qilu Hospital of Shandong University filed Critical Qilu Hospital of Shandong University
Priority to CN202010590308.1A priority Critical patent/CN111690681A/en
Publication of CN111690681A publication Critical patent/CN111690681A/en
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0271—Chimeric vertebrates, e.g. comprising exogenous cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/59—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g.hCG [human chorionic gonadotropin]; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0681—Cells of the genital tract; Non-germinal cells from gonads
    • C12N5/0682—Cells of the female genital tract, e.g. endometrium; Non-germinal cells from ovaries, e.g. ovarian follicle cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0693—Tumour cells; Cancer cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57411—Specifically defined cancers of cervix
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57488—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/70—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving creatine or creatinine
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G01N33/76—Human chorionic gonadotropin including luteinising hormone, follicle stimulating hormone, thyroid stimulating hormone or their receptors
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/12—Animals modified by administration of exogenous cells
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/106—Plasmid DNA for vertebrates
    • C12N2800/107—Plasmid DNA for vertebrates for mammalian

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Endocrinology (AREA)
  • Pathology (AREA)
  • General Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Oncology (AREA)
  • Reproductive Health (AREA)
  • Environmental Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Animal Husbandry (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Toxicology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

The invention discloses a real-time monitoring method for a cervical cancer SiHa cell line beta-hCG, in particular to the field of tumor cell monitoring methods, which comprises the following operation steps: s1, establishing a SiHa cell line for stably expressing beta hCG by transfecting a pCIneo-beta hCG plasmid; s2, subcutaneously inoculating BALB/C mice to establish a tumor model, monitoring the growth condition of the tumor by monitoring the urine beta-hCG/creatinine ratio, and monitoring the anti-tumor effect of the urine beta-hCG/creatinine ratio after the abdominal cavity cis-platinum chemotherapy. The invention adopts molecular biology means to invent an animal model for secreting a tumor marker beta-hCG, and is used for monitoring the change of the size of a tumor in vitro.

Description

Real-time monitoring method for cervical cancer SiHa cell line beta-hCG
Technical Field
The embodiment of the invention relates to the technical field of tumor cell monitoring methods, and in particular relates to a real-time monitoring method for a cervical cancer SiHa cell line beta-hCG.
Background
Cervical cancer is the second largest tumor in women, accounting for about 25% of women's malignant tumors, causing about 20 million deaths per year, and the research on prevention and treatment of cervical cancer is very extensive. Animal models are very commonly used for cervical cancer research, particularly, the measurement of tumor size is significant for tumor prevention and treatment research, but the existing cervical cancer animal models generally estimate the size of animal tumors by injecting tumor cells under the skin of animals through visual inspection and gross touch, have large errors and are difficult to quantify, and the quantity of metastatic and infiltrated tumor cells is difficult to evaluate. Animals can only be sacrificed for quantitative determination of tumor size, and the tumor is dissected out, so that the change of the tumor can be researched only by one time point, and the dynamic change of tumor cells in vivo can not be continuously researched.
The two subunits (β -hCG) of human chorionic gonadotropin β are used as the index for detecting gestational trophoblastic tumor for a long time, the content of blood and urine β -hCG is in good positive correlation with the size of the tumor, and the in vitro detection of the existence and the size of the tumor is very convenient[2]On the basis, a set of simple and easy real-time monitoring system for tumor cell metabolism is established by Shih professor of John Hopkins university[1]The invention refers to the system, the pCIneo-hCG plasmid is transferred into SiHa cervical cancer cell line, and the cervical cancer cell carrying β -hCG gene is inoculated to an immunodeficiency mouse to form a tumor-bearing animal model, thereby establishing a cervical cancer real-time monitoring model and evaluating the relation between β -hCG secretion and tumor growth and treatment.
Disclosure of Invention
Therefore, the embodiment of the invention provides a real-time monitoring method for a cervical cancer SiHa cell line beta-hCG, which artificially adds a tumor marker beta-hCG to tumor cells by adopting a molecular biology means so as to monitor the change of the tumor size and solve the problems in the prior art.
In order to achieve the above object, the embodiments of the present invention provide the following technical solutions: a real-time monitoring method for a cervical cancer SiHa cell line beta-hCG comprises the following operation steps:
s1, establishing a SiHa cell line for stably expressing beta hCG by transfecting a pCIneo-beta hCG plasmid;
s2, subcutaneously inoculating BALB/C mice to establish a tumor model, monitoring the growth condition of the tumor by monitoring the urine beta-hCG/creatinine ratio, and monitoring the anti-tumor effect of the urine beta-hCG/creatinine ratio after the abdominal cavity cis-platinum chemotherapy.
Further, in step S1, the SiHa cell line is established as follows:
s1.1, plasmid amplification, extraction and identification:
1) conventionally transforming DH5 alpha competent bacteria prepared by a CaCl2 method with pCIneo-beta hCG plasmid, inoculating LA plate for screening, selecting single colony, inoculating the single colony in LA liquid culture medium, and culturing overnight;
2) adopting SDS alkali to crack a small amount of extracted plasmid DNA according to the specification of the plasmid extraction kit, placing the plasmid DNA in an Elutionbuffer, detecting the concentration of the plasmid DNA by an ultraviolet spectrophotometer, adopting Sac I and Kpn I double enzyme digestion and KpnI single enzyme digestion agarose gel electrophoresis, EB dyeing, observing, scanning and recording;
s1.2, cell culture and establishment of a beta hCG stable expression cell line;
1) the SiHa cells adopt DMEM + 10% fetal calf serum, so that the growth and transfection effects of the cells are not influenced, antibiotics are not used, the SiHa cells are placed in a 5% carbon dioxide incubator at 37 ℃ for culture, the cells are normally subjected to liquid change once every 2 days, and 0.25% pancreatic enzyme digestion passage is carried out;
2) inoculating a 24-well plate with 10e5 cells according to the instructions of a lipofectin2000 transfection kit, culturing for 36 hours in a complete culture medium, transfecting the cells with a serum-free culture medium according to the proportion of 0.8ug of plasmid and 4uL of lipofectin2000 when the cells are more than 90% full, and replacing the complete culture medium after culturing for 4 hours in a 5% carbon dioxide incubator at 37 ℃;
3) digesting and subculturing at a ratio of 1:5 after 48 hours, culturing for 12 hours, adding G418 with a screening dose after the cells are attached to the wall, selecting SiHa cells with a screening dose of 750ug/uL according to literature and pre-test results, picking single cell colonies after 5 days, completely culturing in a culture medium, adding G418 with a maintenance dose to maintain the screening pressure and the maintenance dose of 200ug/mL, and continuously culturing for 20 days to perform the test[5]The established cell line was named SiHa-hCG.
Further, in step S1, the step of detecting the expression of hCG in the cell comprises:
after digestion and passage, SiHa cells after stable transfection are inoculated into a 24-well plate by a concentration gradient of 5 × 10E 4/well for 4 wells, 1mL of complete culture medium is respectively added, after 24h, culture medium supernatant is sucked, a Roche E170 electrochemical luminescence detector is used for detecting the content of beta-hCG, and untransfected SiHa cells are treated as normal controls.
Further, in step S1, the method for evaluating the presence or absence of a change in the growth state of cells after stably transfecting the β -hCG gene is an MTT growth curve assay comprising:
adopting MTT growth curve experiment verification, after carrying out routine passage on beta-HCG transfected and untransfected Hela and SiHa cell pancreatin, inoculating a 96-well plate with 10e 3/well cells and 100 ul/well culture medium, repeating the wells in 4 wells in each group for 6 blocks, changing the liquid once every 2 days, taking out 1 block every day for MTT determination, adding 10ul MTT (5mg/ml) to each well, culturing for 4 hours at 37 ℃, removing the culture medium, adding 100ul DMSO to each well, measuring absorbance at 570nm after shaking and dissolving, and drawing a growth curve.
Further, in step S2, the tumor cell monitoring method is as follows:
s2.1, establishing a tumor-bearing mouse;
1) selecting healthy female BALB/C mice, culturing the mice under the conditions of 6-8 weeks old, 20-25g of body weight and SPF (specific pathogen free), respectively inoculating 3 SiHa cells into each female BALB/C mouse by using 1 × 10e7 cells under the subcutaneous condition, using the mice as a control group, collecting urine once every 2 days, killing the mice after 15 days, dissecting tumors and weighing the tumors;
2) 12 SiHa-hCG cells are additionally inoculated, urine is collected every 2 days for measurement, 3 mice are respectively killed on the 9 th day, the 11 th day, the 13 th day and the 15 th day and are respectively marked as 1 group, 2 groups, 3 groups and 4 groups of an anatomical test, the weights of tumors are weighed, and correlation analysis is carried out on the urine beta-hCG/creatinine ratio;
s2.2, influence of cisplatin abdominal cavity chemotherapy on a urine beta-hCG/creatinine ratio;
inoculating SiHa-hCG cells to 3 mice according to the method, recording as a chemotherapy test group, collecting urine every 2 days for measurement, injecting cisplatin into the abdominal cavity after 15 days when obvious tumors appear subcutaneously, injecting the cisplatin into the abdominal cavity once every day on 15 days and 18 days, and recording the change of the urine beta-hCG/creatinine ratio value to 21 days after 2 times;
s2.3, collecting and measuring urine of the mouse;
at 5 pm every day, the mice are placed in a small cage with a clean old 96-well plate, after 3h, urine of the mice is collected, the amount of β -hCG in the urine is detected by a Roche E-170 electrochemical luminometer, the influence of receptor fluid balance is small because urine creatinine is relatively constant, and the influence of urine concentration can be shielded by calculating the ratio of β -hCG/creatinine[3]The content of β -hCG in blood is truly reflected by introducing urine creatinine for standardization[4]The amount of urinary creatinine was measured by a Jaffe reaction method using a Roche 7600 full-automatic biochemical analyzer.
Further, in step S2.1, the specific method for collecting urine every two days is as follows: collected once on day 0, day 1, and every 2 days thereafter.
Further, in step S2, the data analysis uses SPSS 11.5 statistical analysis software, and the line graph drawing uses Excel 2003 software.
The embodiment of the invention has the following advantages:
1. the invention adopts a molecular biology means, invents an animal model for secreting a tumor marker beta-hCG, and is used for monitoring the change of the size of a tumor;
2. the in vitro growth curve test of the invention shows that the growth characteristics of SiHa cells are not obviously changed by introducing the beta-hCG gene, and the in vivo tumor inoculation test also shows that the tumorigenicity and growth capacity of the SiHa cells are not obviously changed after introducing the beta-hCG gene; the dissection experiment shows that: the ratio of beta hCG to creatinine in mouse urine is in linear positive correlation with the weight of SiHa-hCG tumor in vivo, and the test system has obvious effect on monitoring the growth of tumor in animal body;
3. at present, because the beta hCG determination and the creatinine determination are both items routinely developed by clinical laboratory, the establishment of a tumor beta hCG expression cell line is successful, and the system is a simple, convenient and ideal real-time tumor growth monitoring system, so the system has wide application prospect.
Drawings
In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings used in the description of the embodiments or the prior art will be briefly described below. It should be apparent that the drawings in the following description are merely exemplary, and that other embodiments can be derived from the drawings provided by those of ordinary skill in the art without inventive effort.
The structures, ratios, sizes, and the like shown in the present specification are only used for matching with the contents disclosed in the specification, so as to be understood and read by those skilled in the art, and are not used to limit the conditions that the present invention can be implemented, so that the present invention has no technical significance, and any structural modifications, changes in the ratio relationship, or adjustments of the sizes, without affecting the effects and the achievable by the present invention, should still fall within the range that the technical contents disclosed in the present invention can cover.
FIG. 1 is a schematic diagram of the enzyme digestion electrophoresis of pCI-neo-beta hCG provided by the present invention;
FIG. 2 is a schematic diagram showing the morphological comparison in the SiHa cell transfection process provided by the present invention;
FIG. 3 is a comparative schematic diagram of SiHa-hCG and SiHa cell growth curves provided by the present invention;
FIG. 4 is a schematic representation of the relationship between urine β hCG/creatinine ratio and tumor growth provided by the present invention;
FIG. 5 is a graph showing tumor weight versus urine β hCG/creatinine ratio provided by the present invention;
FIG. 6 is a schematic diagram of the effect of the SiHa-hCG tumor model for treating cervical cancer by detecting the urine beta hCG/creatinine ratio and performing intraperitoneal injection with cisplatin.
Detailed Description
The present invention is described in terms of particular embodiments, other advantages and features of the invention will become apparent to those skilled in the art from the following disclosure, and it is to be understood that the described embodiments are merely exemplary of the invention and that it is not intended to limit the invention to the particular embodiments disclosed. All other embodiments, which can be derived by a person skilled in the art from the embodiments given herein without making any creative effort, shall fall within the protection scope of the present invention.
Example 1
The method for monitoring the cervical cancer SiHa cell line beta-hCG in real time comprises the following operation steps:
s1, establishing a SiHa cell line for stably expressing beta hCG by transfecting a pCIneo-beta hCG plasmid;
the SiHa cell line was established as follows:
s1.1, plasmid amplification, extraction and identification:
1) conventionally transforming DH5 alpha competent bacteria prepared by a CaCl2 method with pCIneo-beta hCG plasmid, inoculating LA plate for screening, selecting single colony, inoculating the single colony in LA liquid culture medium, and culturing overnight;
2) according to the description of the plasmid extraction kit (TaKaRa MiniBEST V2.0 is adopted as the plasmid extraction kit), SDS alkali is adopted to crack a small amount of plasmid DNA, the plasmid DNA is placed in an Elution Buffer, an ultraviolet spectrophotometer is used to detect the concentration of the plasmid DNA, the SacI and Kpn I double enzyme digestion and Kpn I single enzyme digestion agarose gel electrophoresis are adopted, EB staining is carried out, observation and scanning recording are carried out;
s1.2, cell culture and establishment of a beta hCG stable expression cell line;
1) the SiHa cells adopt DMEM + 10% fetal calf serum, so that the growth and transfection effects of the cells are not influenced, antibiotics are not used, the SiHa cells are placed in a 5% carbon dioxide incubator at 37 ℃ for culture, the cells are normally subjected to liquid change once every 2 days, and 0.25% pancreatic enzyme digestion passage is carried out;
2) inoculating a 24-well plate with 10e5 cells according to the instructions of a lipofectin2000 transfection kit, culturing for 36 hours in a complete culture medium, transfecting the cells with a serum-free culture medium according to the proportion of 0.8ug of plasmid and 4uL of lipofectin2000 when the cells are more than 90% full, and replacing the complete culture medium after culturing for 4 hours in a 5% carbon dioxide incubator at 37 ℃;
3) after 48 hours, digesting and passaging according to a ratio of 1:5, culturing for 12 hours, adding a screening dose of G418 after the cells are attached to the wall, and performing preliminary experiment according to the results of the literatureiHa the screening dose of the cells is 750ug/uL, after 5 days, picking single cell colony, culturing in complete culture medium, adding maintenance dose of G418 to maintain screening pressure, and maintaining dose of 200ug/mL, and culturing for 20 days to obtain test[5]The established cell line is named SiHa-hCG;
the detection step of the expression of the cellular hCG comprises the following steps:
after digestion and passage of stably transfected SiHa cells, inoculating the SiHa cells into a 24-pore plate by using a concentration gradient of 5 × 10E 4/pore, adding 1mL of complete culture medium into the SiHa cells for 4 pores in total, respectively, sucking the supernatant of the culture medium after 24 hours, detecting the content of beta-hCG by using a Roche E170 electrochemical luminescence detector, and treating the untransfected SiHa cells as normal control in the same way;
the method for evaluating the presence or absence of a change in the growth state of cells after stable transfection of the β -hCG gene is an MTT growth curve assay comprising:
adopting MTT growth curve experiment verification, after carrying out conventional passage on beta-HCG transfected and untransfected Hela and SiHa cell pancreatin, inoculating a 96-well plate with 10e 3/well cells and 100 ul/well culture medium, repeating the holes in each group with 4 holes, changing the liquid once every 2 days, taking out 1 block every day for MTT determination, adding 10ul MTT (5mg/ml) to each hole, culturing for 4 hours at 37 ℃, removing the culture medium, adding 100ul DMSO to each hole, measuring absorbance at 570nm after shaking and dissolving, and drawing a growth curve;
s2, subcutaneously inoculating a BALB/C mouse to establish a tumor model, monitoring the growth condition of the tumor by monitoring the urine beta-hCG/creatinine ratio, and monitoring the anti-tumor effect of the urine beta-hCG/creatinine ratio after the abdominal cavity cis-platinum chemotherapy;
the tumor cell monitoring method is as follows:
s2.1, establishing a tumor-bearing mouse;
1) selecting healthy female BALB/C mice, culturing the mice under the conditions of 6-8 weeks old, 20-25g of body weight and SPF (specific pathogen free), respectively inoculating 3 SiHa cells into each female BALB/C mouse by using 1 × 10e7 cells under the subcutaneous condition, using the mice as a control group, collecting urine once every 2 days, killing the mice after 15 days, dissecting tumors and weighing the tumors;
2) 12 SiHa-hCG cells are additionally inoculated, urine is collected every 2 days for measurement, 3 mice are respectively killed on the 9 th day, the 11 th day, the 13 th day and the 15 th day and are respectively marked as 1 group, 2 groups, 3 groups and 4 groups of an anatomical test, the weights of tumors are weighed, and correlation analysis is carried out on the urine beta-hCG/creatinine ratio;
s2.2, influence of cisplatin abdominal cavity chemotherapy on a urine beta-hCG/creatinine ratio;
inoculating SiHa-hCG cells to 3 mice according to the method, recording as a chemotherapy test group, collecting urine every 2 days for measurement, injecting cisplatin into the abdominal cavity after 15 days when obvious tumors appear subcutaneously, injecting the cisplatin into the abdominal cavity once every day on 15 days and 18 days, and recording the change of the urine beta-hCG/creatinine ratio value to 21 days after 2 times;
s2.3, collecting and measuring urine of the mouse;
at 5 pm every day, the mice are placed in a small cage with a clean old 96-well plate, after 3h, urine of the mice is collected, the amount of β -hCG in the urine is detected by a Roche E-170 electrochemical luminometer, the influence of receptor fluid balance is small because urine creatinine is relatively constant, and the influence of urine concentration can be shielded by calculating the ratio of β -hCG/creatinine[3]The content of β -hCG in blood is truly reflected by introducing urine creatinine for standardization[4]The amount of urinary creatinine was measured by a Jaffe reaction method using a Roche 7600 full-automatic biochemical analyzer.
Further, in step S2.1, the specific method for collecting urine every two days is as follows: collected once on day 0, day 1, and every 2 days thereafter.
Further, in step S2, the data analysis uses SPSS 11.5 statistical analysis software, and the line graph drawing uses Excel 2003 software.
BALB/C mice are purchased from the animal experiment center of Shandong university, and the beta-hCG detection adopts a Roche E170 electrochemical luminescence detector, a Roche HCG + beta kit and electrochemical luminescence immunoassay; creatinine is detected by adopting a Roche 7600 full-automatic biochemical analyzer, a Roche CREA kit and a Jaffe reaction method; MTT is a product of Sigma company.
Example 2
And (3) plasmid amplification and identification:
the ultraviolet spectrophotometer detects that the concentration of the pCIneo-beta hCG plasmid DNA is about 200ng/uL, the digestion sites of Sac I and Kpn I are positioned at the positions of carriers 729, 1112 and 2051bp, the digestion site of Kpn I at the position of 1112bp is damaged by the pCI-neo-beta hCG plasmid due to the insertion of a target gene, and the length of a fragment generated by double digestion is 4152 and 1833 bp. The Marker uses lambda DNA/Hind III + EcoRI.
The cleavage and identification results of the pCI-neo-beta hCG plasmid are shown in FIG. 1, and in FIG. 1: m: marker; 1: double enzyme digestion electrophoresis; 2: single enzyme digestion electrophoresis.
Example 3
Cell culture and transfection: comparison of cell culture before and after transfection of pCIneo-hCG plasmid and single cell cloning are shown in FIG. 2.
Example 4
SiHa cell beta hCG expression assay, see in particular FIG. 2;
the results of measuring the content of β hCG in the culture supernatants of SiHa cells and SiHa-hCG cells are shown in table 1:
table 1: SiHa cell and SiHa-hCG cell culture supernatant beta hCG content assay results (miU/mL)
Figure BDA0002556086340000081
The two samples are tested by t, t is 59.91, P is 0.0000, the difference is obvious, the SiHa-hCG cell expresses the beta hCG quantity which is far higher than that of the normal SiHa cell, and the SiHa-hCG cell line is successfully established.
Example 5
And (3) measuring a growth curve:
as shown in FIG. 3, SiHa-hCG and SiHa cell growth curves substantially coincide, demonstrating that the introduction of the β hCG gene did not significantly affect cell growth.
Example 6
Tumor weight comparisons of mice inoculated with SiHa-hCG and SiHa cells, see Table 2;
dissecting test 4 and control groups of 3 mice each, inoculated with the same number of SiHa-hCG and SiHa cells, sacrificed at day 15, and dissected to weigh the tumor, the results were as follows:
TABLE 2 tumor weights at day 15 in mice inoculated with SiHa-hCG and SiHa cells
Tumor weight (g) of mice inoculated with cells
SiHa 1.48 1.51 1.73
SiHa-hCG 1.38 1.62 1.85
The two sets of data were examined using SPSS two-sample mean t test, t-0.2509, P-0.8143 >0.05, so the two overall means could not be considered equal, i.e., the difference in cell growth rates between SiHa-hCG and SiHa could not be considered.
Example 7
Correlation of mouse urine β hCG/creatinine ratio with tumor growth:
as described in steps S2.1 and S2.2, a total of 6 SiHa-hCG vaccinated mice survived to day 15 without any further treatment (dissected test 4 and chemotherapy test groups), and their urine β hCG/creatinine ratio was correlated with tumor growth as shown in fig. 4 and 5. The low-level curve is the change in urine β hCG/creatinine ratio in mice vaccinated with normal SiHa cells (control). As can be seen from the figure: the urinary β hCG/creatinine ratio increased gradually with tumor growth for SiHa-hCG vaccinated mice, while the urinary β hCG/creatinine ratio for normal SiHa-cell vaccinated mice remained at baseline.
The relationship between the tumor weight obtained by dissecting 12 mice and the urine beta hCG/creatinine ratio at the same day is analyzed by SPSS 11.5 linear correlation: correlation coefficient (r) is 0.983, hypothesis test of correlation coefficient: t 16.865 and P0.000, a linear correlation between tumor weight and urine β hCG/creatinine ratio is believed to be present.
Example 8
Mouse urine beta hCG/creatinine was examined for the effect of cisplatin intraperitoneal injection in the treatment of the SiHa-hCG tumor model, as shown in FIG. 6.
And (4) conclusion:
in the research of prevention and treatment of cervical cancer, animal models are indispensable, but an ideal means for monitoring the size of tumor has been lacking, and it is not easy to select an ideal tumor marker to detect the size of tumor, and it is difficult to identify the tumor.
Human Chorionic Gonadotropin (hCG) is a glycoprotein hormone consisting of two subunits, alpha and beta, each of which has no hormonal activity in the free state. The beta subunit is specific to HCG, can be discharged from urine, is convenient to detect, and can be used as a tumor marker of gestational trophoblastic tumor for a long time.
The growth curve test in vitro shows that the growth characteristics of SiHa cells are not obviously changed by the introduction of the beta-hCG gene, and the tumor inoculation test in vivo also shows that the tumorigenicity and growth capacity of the SiHa cells are not obviously changed after the introduction of the beta-hCG gene.
Anatomical tests show that the mouse urine β hCG/creatinine ratio is linearly and positively correlated with the SiHa-hCG tumor weight in vivo, the correlation coefficient (r) is 0.983. the mouse urine β hCG/creatinine ratio is gradually increased along with the tumor growth, after cis-platinum chemotherapy, the survival tumor cells in the mouse are reduced, and the urine β hCG/creatinine ratio is rapidly reduced[1]。
The number of animals used in the invention is small at present, and the number of animals is further increased in future, and whether the tumorigenicity of the tumor cells is changed after the beta hCG gene transfection is commented.
Reference to the literature
1、Shin IM,Torrance C,Sokoll LJ.Et al.Assessing tumors in livinganimals through measurement of urinary beta-human chronic gonadotropin.NatMed.2000,6(6):711-4
2、Cole,L.hCG,its free subunits and its metabolites：Roles in pregnancyand trophoblastic disease.J.Reprod.Med.43,3–10(1998).
3、Alessio L,BerlinA,Dell`OrtoA,Et al.Reliability ofurinary creatinineas a parameter used to adjust values of urinary biological indicators.IntArch Occup Environ Health.1985(55):99-106.
4. Zhang Peihai, Van Jun, Wang Shi Hua, etc. Analysis of the value of urine β -HCG quantification in the therapeutic monitoring of pregnancy-related diseases, journal of obstetrics and gynecology 2003, 19 (1): 30-31
5. Caoya, practical molecular biology guidelines [ M ], beijing, national institutes of health, 2003: 204-207.
Although the invention has been described in detail above with reference to a general description and specific examples, it will be apparent to one skilled in the art that modifications or improvements may be made thereto based on the invention. Accordingly, such modifications and improvements are intended to be within the scope of the invention as claimed.

Claims (7)

1. A real-time monitoring method for a cervical cancer SiHa cell line beta-hCG is characterized by comprising the following steps: the method comprises the following operation steps:
s1, establishing a SiHa cell line for stably expressing beta hCG by transfecting a pCIneo-beta hCG plasmid;
s2, subcutaneously inoculating BALB/C mice to establish a tumor model, monitoring the growth condition of the tumor by monitoring the urine beta-hCG/creatinine ratio, and monitoring the anti-tumor effect of the urine beta-hCG/creatinine ratio after the abdominal cavity cis-platinum chemotherapy.
2. The method for real-time monitoring of the cervical cancer SiHa cell line beta-hCG according to claim 1, wherein: in step S1, the SiHa cell line is established as follows:
s1.1, plasmid amplification, extraction and identification:
1) conventionally transforming DH5 alpha competent bacteria prepared by a CaCl2 method with pCIneo-beta hCG plasmid, inoculating LA plate for screening, selecting single colony, inoculating the single colony in LA liquid culture medium, and culturing overnight;
2) adopting SDS alkali to crack a small amount of extracted plasmid DNA according to the specification of the plasmid extraction kit, placing the plasmid DNA in an Elutionbuffer, detecting the concentration of the plasmid DNA by an ultraviolet spectrophotometer, adopting Sac I and Kpn I double enzyme digestion and Kpn I single enzyme digestion agarose gel electrophoresis, EB dyeing, observing, scanning and recording;
s1.2, cell culture and establishment of a beta hCG stable expression cell line;
1) SiHa cells adopt DMEM + 10% fetal calf serum, are placed in a 5% carbon dioxide incubator at 37 ℃ for culture, change the liquid once every 2 days, and are digested and passed by 0.25% pancreatin;
2) inoculating a 24-well plate with 10e5 cells according to the instructions of a lipofectin2000 transfection kit, culturing for 36 hours in a complete culture medium, transfecting the cells with a serum-free culture medium according to the proportion of 0.8ug of plasmid and 4uL of lipofectin2000 when the cells are more than 90% full, and replacing the complete culture medium after culturing for 4 hours in a 5% carbon dioxide incubator at 37 ℃;
3) after 48 hours, digesting and passaging according to a ratio of 1:5, culturing for 12 hours, adding G418 with a screening dose after the cells adhere to the walls, according to the literature and the pre-test results, the screening dose of SiHa cells is 750ug/uL, picking single cell colonies after 5 days, completely culturing in a culture medium, adding G418 with a maintenance dose to maintain the screening pressure, the maintenance dose is 200ug/mL, continuously culturing for 20 days, and then testing, wherein the established cell line is named as SiHa-hCG.
3. The method for real-time monitoring of the cervical cancer SiHa cell line beta-hCG according to claim 1, wherein: in step S1, the step of detecting the expression of cellular hCG comprises:
after digestion and passage, SiHa cells after stable transfection are inoculated into a 24-well plate by a concentration gradient of 5 × 10E 4/well for 4 wells, 1mL of complete culture medium is respectively added, after 24h, culture medium supernatant is sucked, a Roche E170 electrochemical luminescence detector is used for detecting the content of beta-hCG, and untransfected SiHa cells are treated as normal controls.
4. The method for real-time monitoring of the cervical cancer SiHa cell line beta-hCG according to claim 1, wherein: in step S1, the method for evaluating the presence or absence of a change in the growth state of cells after stable transfection of the β -hCG gene is MTT growth curve assay comprising:
adopting MTT growth curve experiment verification, after carrying out routine passage on beta-HCG transfected and untransfected Hela and SiHa cell pancreatin, inoculating a 96-well plate with 10e 3/well cells and 100 ul/well culture medium, repeating the wells in 4 wells in each group for 6 blocks, changing the liquid once every 2 days, taking out 1 block every day for MTT determination, adding 10ul MTT (5mg/ml) to each well, culturing for 4 hours at 37 ℃, removing the culture medium, adding 100ul DMSO to each well, measuring absorbance at 570nm after shaking and dissolving, and drawing a growth curve.
5. The method for real-time monitoring of the cervical cancer SiHa cell line beta-hCG according to claim 1, wherein: in step S2, the tumor cell monitoring method is as follows:
s2.1, establishing a tumor-bearing mouse;
1) selecting healthy female BALB/C mice, culturing the mice under the conditions of 6-8 weeks old, 20-25g of body weight and SPF (specific pathogen free), respectively inoculating 3 SiHa cells into each female BALB/C mouse by using 1 × 10e7 cells under the subcutaneous condition, using the mice as a control group, collecting urine once every 2 days, killing the mice after 15 days, dissecting tumors and weighing the tumors;
2) 12 SiHa-hCG cells are additionally inoculated, urine is collected every 2 days for measurement, 3 mice are respectively killed on the 9 th day, the 11 th day, the 13 th day and the 15 th day and are respectively marked as 1 group, 2 groups, 3 groups and 4 groups of an anatomical test, the weights of tumors are weighed, and correlation analysis is carried out on the urine beta-hCG/creatinine ratio;
s2.2, influence of cisplatin abdominal cavity chemotherapy on a urine beta-hCG/creatinine ratio;
inoculating SiHa-hCG cells to 3 mice according to the method, recording as a chemotherapy test group, collecting urine every 2 days for measurement, injecting cisplatin into the abdominal cavity after 15 days when obvious tumors appear subcutaneously, injecting the cisplatin into the abdominal cavity once every day on 15 days and 18 days, and recording the change of the urine beta-hCG/creatinine ratio value to 21 days after 2 times;
s2.3, collecting and measuring urine of the mouse;
at 5 pm every day, the mouse is placed into a small cage paved with a clean old 96-well plate, after 3 hours, urine of the mouse is collected, a Roche E-170 electrochemical luminometer is used for detecting the amount of beta-hCG in the urine, urinary creatinine is introduced to be standardized to truly reflect the content of the beta-hCG in blood, and the amount of the urinary creatinine is measured by a Jaffe reaction method by using a Roche 7600 full-automatic biochemical analyzer.
6. The method for real-time monitoring of the cervical cancer SiHa cell line beta-hCG according to claim 5, wherein: in step S2.1, the specific method of collecting urine every two days is: collected once on day 0, day 1, and every 2 days thereafter.
7. The method for real-time monitoring of the cervical cancer SiHa cell line beta-hCG according to claim 5, wherein: in step S2, the data analysis was performed using SPSS 11.5 statistical analysis software, and the line graph was drawn using Excel 2003 software.
CN202010590308.1A 2020-06-24 2020-06-24 Real-time monitoring method for cervical cancer SiHa cell line beta-hCG Pending CN111690681A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202010590308.1A CN111690681A (en) 2020-06-24 2020-06-24 Real-time monitoring method for cervical cancer SiHa cell line beta-hCG

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202010590308.1A CN111690681A (en) 2020-06-24 2020-06-24 Real-time monitoring method for cervical cancer SiHa cell line beta-hCG

Publications (1)

Publication Number Publication Date
CN111690681A true CN111690681A (en) 2020-09-22

Family

ID=72484020

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202010590308.1A Pending CN111690681A (en) 2020-06-24 2020-06-24 Real-time monitoring method for cervical cancer SiHa cell line beta-hCG

Country Status (1)

Country Link
CN (1) CN111690681A (en)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6419896B1 (en) * 2000-03-03 2002-07-16 Bert Vogelstein Non-invasive approach for assessing tumors in living animals
CN1935266A (en) * 2005-09-23 2007-03-28 中国科学院动物研究所 Method for establishing mouse breast cancer tumour model for trans hCG beta gene

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6419896B1 (en) * 2000-03-03 2002-07-16 Bert Vogelstein Non-invasive approach for assessing tumors in living animals
CN1935266A (en) * 2005-09-23 2007-03-28 中国科学院动物研究所 Method for establishing mouse breast cancer tumour model for trans hCG beta gene

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
姜育燊: "宫颈癌SiHa细胞系β-hCG表达体系在肿瘤监控动物模型中的应用", 《中国优秀博硕士学位论文全文数据库（硕士） 医药卫生科技辑》 *

Similar Documents

Publication Publication Date Title
CN1916183B (en) Method for establishing cell line by chromosome karyotype for analyzing quality control for medical field
CN103627673A (en) Human brain glioma cell line, and establishing method and application thereof
CN103333858B (en) Gleevec-resistant gastrointestinal stromal tumor cell line, method thereof, and nude mouse transplantation tumor model thereof
CN113652392B (en) Cosmetic anti-inflammatory efficacy assessment method based on in-vitro macrophage and 3D skin model co-culture
Mustafa et al. Male infertility treatment unveiled: exploring new horizons with Q-well 10-results from a pioneering medical study
CN108660212B (en) Application of WDR1 gene in preparation of non-small cell lung cancer treatment and detection products
CN111690681A (en) Real-time monitoring method for cervical cancer SiHa cell line beta-hCG
CN113633775A (en) Application of agent for over-expressing phosphofructokinase in preparation of drugs for delaying cell senescence
CN109868313A (en) Application of the HMGA2 gene in Stein-Leventhal syndrome disease
Serafini et al. Endometrial leukemia inhibitory factor as a predictor of pregnancy after in vitro fertilization
CN104789684A (en) Kit applied to embryonic development quality evaluation and use method
Li et al. LINC00323 mediates the role of M1 macrophage polarization in diabetic nephropathy through PI3K/AKT signaling pathway
CN111363721A (en) Docetaxel-induced established luminal breast cancer multidrug-resistant cell strain and construction method and application thereof
CN110684818A (en) Application of real-time unmarked cell analyzer in detecting proliferation and migration capacity of esophageal cancer cells
CN108913770A (en) It is a kind of to utilize newborn's TRECs and KRECs gene copy number detection kit of digital pcr technology and its application
CN114959033A (en) Application of exosome piRNA
Osborne et al. Endocrine therapy testing of human breast cancers in the soft agar clonogenic assay
CN114457161A (en) Application of lncRNA AC145207.5 in colorectal cancer diagnosis, treatment and drug sensitivity improvement
Shen et al. Effect of BMI on the value of serum progesterone to predict clinical pregnancy outcome in IVF/ICSI cycles: a retrospective cohort study
CN104403996B (en) Human gastric cancer cell line with 5-fluorouracil resistance and establishment method and application thereof
CN109929804B (en) Human ovarian cancer cell line and preparation method and application thereof
CN103451303B (en) Kit for detecting expression level of human ERCC1 (excision repair cross complementation 1) through PCR (polymerase chain reaction) method
CN105505936A (en) Metastasis of osteosarcoma resistant biological agent and preparation method thereof
CN111440868A (en) Laryngeal squamous carcinoma molecular marker hsa _ circ _0018169 and detection method and application thereof
Zhao et al. MDM4 is targeted by miR-449b-5p to promote the proliferation of endometrial carcinoma.

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20200922

RJ01 Rejection of invention patent application after publication